NEXTCLINICS Services GmbH, based in Bregenz/Austria, dealing with the worldwide distribution of consumables for IVF centers.
In addition, we are general agent of Vitrisafe,
a vitrification system for egg cells and embryos.
Corona has once again started the discussion about possible contamination of oocytes and embryos by contaminated or infected LN2 when using open systems for cryopreservation.
With this in mind, we started developing the VitriSafe as a closed system almost 20 years ago, because we could not imagine getting a CE approval with such a risk. Nevertheless, well-known manufacturers have obtained this approval while negating this risk.
Since we have shown with the VitriSafe that even with a closed system at least equally good results can be achieved respectively for oocytes and embryos, despite the slower cooling rate, and that handling is simple and safe, we do not consider it responsible to continue using open systems in view of the current
Corona / Covid-19 epidemic.
VitriSafe also makes it possible to easily disinfect the area where the straw is going to be cut, while guaranteeing the viability of the oocytes and embryos.
It would be necessary to communicate this more strongly to the embryologists and to point out that the VitriSafe is a closed system that has proven for years that it is easy to use and that excellent results can be achieved just as well as with open systems.
The establishment of this effective technique of cryopreservation was a landmark in reproductive medicine.
According to the EU Directive on stem cells and tissues, embryos or oocytes must be optimally protected from contamination with pathogens or harmful chemical substances both in the process of cryopreservation and also during the storage in liquid nitrogen. ased on current knowledge, this can only be guaranteed by a “closed” or aseptic carrier system. Since the vitrification with such carrier devices is technically very challenging, with VitriSafe we have developed our own and highly effective system.
Apart from the trouble-free operation, the cells are protected from contamination, thus ensuring a consistently high survival rate with respect to all stages of cell development. After incubation in the vitrification solutions, the oocytes can be easily picked up and placed on the “VitriSafe” carrier device in a very small volume (< 1 µl) of vitrification medium.
The VitriSafe is then inserted in the protective straw. Both edges of the protective straw are subsequently welded. Thus, the oocytes/embryos are protected from direct contact with liquid nitrogen into which the straw is then immersed.
Advantages of the method:
- No direct contact with liquid nitrogen
- Aseptic carrier device, hermetically sealed
- No risk from contamination with pathogens
- Easy handling
High survival rates for:
- Pronuclear stages
- Day 2 and day 3 embryos
- Compacting embryos and early blastocysts on day 4
Clinical trials have shown that very high survival- and implantation rates were achieved by using this procedure. Moreover, the VitriSafe technique has been found to produce stable results, even after an extended storage period.
1 pc. € 5,90 (net)
VIT-S-60 60 pcs. (12 sleeves à 5 sterile pcs.) € 354,00 (net)
VIT-S-300 300 pcs. (60 sleeves à 5 sterile pcs.) € 1770,00 (net)
By a quantity at 300 VitriSafe single we can give you a discount of 10%.
It is possible to provide the matching straws and fitinng ID rods for an additional charge. Please submit a request in the contact form.
Our offers are aimed at medical institutions or wholesealer.
All prices are without obligation and without VAT.
Delivery charge € 20,-- international.
- Invoice (Payment within 14 days)